A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.